Is Wegovy a controlled substance in the UK?

You've searched this because someone told you Wegovy was like a controlled drug — here's what's actually true

It is a question our prescribers hear most weeks, often from people who have read something alarming online or been told by a friend that Wegovy is "restricted" in a way that feels almost illicit. The confusion is understandable. In the United States, discussions about drug scheduling are everywhere, and some of those conversations bleed into UK searches. Add to that the genuine MHRA crackdown on fake pens and black-market supply, and it starts to feel like Wegovy must be in some heightened legal category.

It is not. Under UK law, the Misuse of Drugs Act 1971 creates the controlled drugs framework, covering substances with recognised potential for dependence or abuse, split into Schedules 1 through 5. Semaglutide does not appear on any of those schedules. Wegovy is governed instead by the Human Medicines Regulations 2012, which classifies it as a Prescription-Only Medicine. That is a meaningful legal status, but a different one. A POM cannot be sold without a prescription; it does not, however, trigger the additional record-keeping, quantity limits and handwriting rules that controlled drugs require. You can read more about the specific properties of semaglutide as a medicine in our breakdown of what Wegovy actually contains.

The practical upshot: a GPhC-registered prescriber can issue a Wegovy prescription through normal clinical channels, and a regulated pharmacy can dispense it in the usual way. No special Home Office licence, no controlled drug register entry, no Schedule-specific dispensing label.

POM status still means Wegovy requires clinical assessment every time

Being outside the controlled drugs framework does not make Wegovy freely available. Prescription-Only status is a real barrier to casual purchase, and deliberately so. A prescriber must assess whether the medicine is appropriate for you, taking into account your health history, current medicines, BMI and any weight-related conditions, before any prescription is issued. Without that assessment, supply is unlawful. Full stop.

This matters because a large part of the illicit Wegovy market operates precisely by bypassing clinical review, not by circumventing controlled drug rules. The MHRA has issued repeated warnings about sellers offering GLP-1 medicines through social media and unverified websites, and enforcement actions through 2024 and 2025 resulted in roughly 20 million doses and approximately £45 million worth of illegally traded weight-loss medicines being seized. Some counterfeit pens have contained insulin rather than semaglutide, with serious consequences for people who injected them.

So the classification question and the safety question are linked, even if the law keeps them in separate boxes. The absence of controlled-drug status does not lower the bar for how carefully you should choose your source. If anything, it makes verifying legitimacy more important, because the supply chain for POMs is wide and less visibly policed than the tightly tracked chain for Schedule 2 substances like morphine.

Before starting treatment, it is also worth understanding how Wegovy can interact with hormonal contraception, which is a separate but practically important consideration for many people.

How classification interacts with Wegovy's licensing and NHS status

Wegovy is licensed by the MHRA for weight management in adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. NICE recommends it for NHS use within specialist weight management services, under NICE appraisal TA875, subject to criteria including BMI thresholds and a maximum treatment duration of two years in that setting. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance.

None of those eligibility or commissioning conditions are a feature of drug scheduling; they are clinical and regulatory decisions attached to the product licence. The distinction is worth keeping clear. Controlled drug rules restrict HOW a medicine is handled by pharmacies and prescribers. Licensing rules restrict WHAT the medicine is approved to treat. Both sit apart from whether a prescriber decides, on clinical grounds, that a particular patient should receive it.

For a fuller picture of Wegovy as a treatment, including how it works and what the clinical evidence shows, the Wegovy overview page covers the trial data and the MHRA-approved indication in more detail. And if you are thinking about how blood sugar is affected during treatment, semaglutide's effect on glucose regulation is addressed separately. Questions about where to access a legitimate supply legally are answered in our guide to where to buy Wegovy in the UK.

What to check before obtaining Wegovy from any online provider

Because Wegovy is a POM and not a controlled drug, pharmacies dispensing it do not face the tightest layer of regulatory scrutiny that applies to Schedule 2 and 3 substances. That puts the responsibility for verifying legitimacy squarely with you, the patient. The steps are simple but important.

Check that the pharmacy is registered on the GPhC's online pharmacy register. Every UK-registered pharmacy has a premises registration number you can look up in seconds; ours is 9012878. Check that the service requires a clinical consultation before issuing a prescription: if a site offers to supply Wegovy without one, that is an unlawful arrangement and a genuine safety risk regardless of what classification the medicine carries. Red flags include social media sales, prices far below market rate, and sellers describing their stock as available "without a doctor".

If you are ready to find out whether Wegovy might be suitable for you through a proper clinical assessment, you can check your eligibility with our prescribers. There is no obligation; the consultation is free. Our clinical team reviews every application personally, not algorithmically, the same day it arrives.